Clonotypic analysis of immunoglobulin heavy chain sequences among 44 patients with Waldenström macroglobulinemia.
10.3760/cma.j.cn511374-20211214-00988
- VernacularTitle:华氏巨球蛋白血症患者44例免疫球蛋白重链序列使用特征的分析
- Author:
Jing TANG
1
;
Yi XIA
;
Hua YIN
;
Li WANG
;
Jiazhu WU
;
Ruize CHEN
;
Jinhua LIANG
;
Huayuan ZHU
;
Lei FAN
;
Jianyong LI
;
Wei XU
Author Information
1. Department of Hematology, Jiangsu Provincial People's Hospital (The First Affiliated Hospital of Nanjing Medical University), Nanjing, Jiangsu 210036, China. xuwei10000@hotmail.com.
- Publication Type:Journal Article
- MeSH:
Humans;
Immunoglobulin Heavy Chains/genetics*;
Multigene Family;
Mutation;
Waldenstrom Macroglobulinemia/genetics*
- From:
Chinese Journal of Medical Genetics
2023;40(3):263-268
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the correlation between the mutational status of immunoglobulin heavy chain variable (IGHV) gene with the prognosis of patients with Waldenström macroglobulinemia (WM).
METHODS:Immunoglobulin heavy chain gene (IGH) clonotypic sequence analysis was carried out to assess the mutational status of IGHV in the blood and/or bone marrow samples from 44 WM patients. The usage characteristics of IGHV-IGHD-IGHJ gene was explored.
RESULTS:The most common IGHV subgroup was IGHV3, which was similar to the data from the Institute of Hematology of Chinese Academy of Medical Science. IGHV3-23 (20.45% vs. 15.44%) and IGHV3-74 (11.36% vs. 7.35%) were the main fragments used, which was followed by IGHV4 gene family (15.91% vs. 24.26%). However, no significant correlation was found between the IGHV4 usage and the prognosis of the patients. Should 98% be taken as the cut-off value for the IGHV mutation status, only 5 patients had no IGHV variant, and there was no correlation with the prognosis. Based on the X-tile analysis, 92.6% was re-selected as the cut-off value for the IGHV variant status in such patients. LDH was increased in 26 patients (59.1%) without IGHV variant (P < 0.05), whilst progression-free survival (P < 0.05) and overall survival (P < 0.05) were significantly shorter compared with those with IGHV variants.
CONCLUSION:The usage characteristics of IGHV-IGHD-IGHJ in our patients was similar to reported by the Institute of Hematology of Chinese Academy of Medical Science, albeit that no correlation was found between the IGHV4 usage and the prognosis of the patients. Furthermore, 98% may not be appropriate for distinguishing the IGHV variant status in WM patients.
